کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6000987 1182942 2015 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Venous thromboembolism in patients with chronic lymphocytic leukemia
ترجمه فارسی عنوان
ترومبوآمبولی وریدی در بیماران مبتلا به لوسمی لنفوسیتی مزمن
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی


- Venous thromboembolism (VTE) is a relatively frequent complication in patients with CLL.
- VTE is not associated with shorter overall survival in CLL patients.
- Our findings support the role of CLL in the development of VTE.

IntroductionVenous thromboembolism (VTE) is a major cause of morbidity and mortality in patients (pts) with malignant tumors. Increased risk of VTE is well described in a variety of hematologic malignancies; however, data regarding VTE in chronic lymphocytic leukemia (CLL) is very limited. Patients and methods: We retrospectively analyzed clinical and laboratory data of 346 consecutive pts with CLL followed up at 4th Department of Internal Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic, diagnosed between 1999 and 2011 (males, 64%; median age, 64 years; low/intermediate/high Rai modified risk in 41/47/12%). Results: After a median follow-up of 72 months (range, 26-138), at least one episode of VTE occurred in 38 patients (11%). VTE developed after a median of 34 months from CLL diagnosis. Incidence of VTE was 1.67% per patient year of follow-up. There was a high proportion of unfavourable prognostic factors (advanced Rai stages, unmutated IgVH genes, unfavourable cytogenetics) in pts with VTE. The presence of 0/1/2/3 additional risk factors for VTE was identified in 2/16/14/6 patients. The most common risk factors for VTE besides age (n = 24) were corticosteroid therapy (n = 13), other malignancies (n = 9) and obesity (n = 7). Recurrence of VTE was diagnosed in 7 pts. Performance status ≥ 2 and inherited thrombophilia were significant risk factors for VTE development in univariate and multivariate analysis. VTE was not associated with shorter overall survival. Conclusion: Based on our results, VTE is a relatively frequent complication in patients with CLL. Although most patients had other known risk factors for VTE including CLL treatment, 29% had no risk factors or only age ≥ 60 years. These findings demonstrate the possible role of CLL in the development of VTE.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Thrombosis Research - Volume 136, Issue 6, December 2015, Pages 1082-1086
نویسندگان
, , , , , , ,